EPL Q2 results for FY27 show revenue up 30% year on year to Rs 15,674 million, with EBITDA up 17.6% to Rs 2,960 million and PAT up 5.6% to Rs 1,101 million, IPP Bureau reported on 5 November 2026. Excluding higher raw material prices, underlying revenue growth was 20.3%.
The packaging company’s EBITDA margin was 18.9% as reported and 20.4% on an underlying basis, with ROCE at 18.2%.
How Did EPL’s Business Segments and Regions Perform?
Beauty & Cosmetics grew 42.9% and Oral Care grew 19.2% in the article body. Regionally, East Asia Pacific grew 40.2%, Europe 30.4%, AMESA 28% and the Americas 25.3%, with India growing 30.5% within AMESA.
Personal Care & Beyond accounts for 55% of the portfolio, and sustainable tube formats made up 41% of sales year to date.
What Is the Proposed Indovida Merger?
The proposed merger with Indovida would create a company with combined revenue of $1 billion and a valuation of $2 billion. BSE and NSE issued observation letters on 19 October 2026, and the filing with the NCLT was made on 23 October 2026. The company remains confident of completing the merger within the expected timelines.
Management Comments and Industry Response
Hemant Bakshi, MD & Global CEO, said: “EPL has delivered another standout quarter, achieving 30% revenue growth.” He added: “Beauty & Cosmetics delivered exceptional growth of over 40%” and said “we remain confident in our momentum and confidently reaffirm our near-term guidance.” No share-price reaction or trade-body comment was found in the sources reviewed.
What Happens Next?
The merger with Indovida now awaits the NCLT process, and the company has reaffirmed its near-term guidance.
Frequently Asked Questions
What was EPL’s revenue in Q2 FY27?
EPL reported revenue up 30% year on year to Rs 15,674 million, according to IPP Bureau on 5 November 2026.
What was EPL’s profit in Q2 FY27?
PAT rose 5.6% to Rs 1,101 million, while EBITDA rose 17.6% to Rs 2,960 million.
What is the EPL and Indovida merger?
It is a proposed merger that would create a company with combined revenue of $1 billion and a valuation of $2 billion; the NCLT filing was made on 23 October 2026.
Source: IPP Bureau (Indian Pharma Post), 5 November 2026.
Leave a comment